Mitigating Adverse Events: A Game Changer for Risk-Based Monitoring

The timeliness of bringing new health products and drugs to market for patients is critical. Yet, meeting stringent regulations such as ICH E6 and patient protection requirements during the clinical trial research phase are slowing down time to market and increasing the cost of new products which can be in the millions.

Improving accuracy, security and speed of data capture during site management monitoring is a game changer for getting new products into production and improving patient health faster. During this on-demand webcast, Michael Connolly, Director of Pharma Accounts at Qstream will share with us:

  • Challenges pharma companies are experiencing in risk-based monitoring effectiveness
  • How to pinpoint compliance adherence to ICH EG regulation
  • Strategies to identify gaps in process and knowledge of monitors, and tailor coaching towards them
  • Where these principles can apply in other highly regulated industries

 

Top